NASDAQ:CODXCo-Diagnostics Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Co-Diagnostics Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $8.80 +0.10 (+1.15 %) (As of 04/10/2020 08:00 AM ET) Add Compare Share Today's Range$8.53Now: $8.80▼$9.1350-Day Range$3.01MA: $9.53▼$17.8152-Week Range$0.69Now: $8.80▼$21.75Volume2.47 million shsAverage Volume7.71 million shsMarket Capitalization$241.47 millionP/E RatioN/ADividend YieldN/ABetaN/A ProfileAnalyst RatingsAdvanced ChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsSocial Media Co-Diagnostics, Inc., a molecular diagnostics company, intends to manufacture and sell reagents used for diagnostic tests that function via the detection and/or analysis of nucleic acid molecules. It also intends to sell diagnostic equipment from other manufacturers as self-contained lab systems. Co-Diagnostics, Inc. was founded in 2013 and is headquartered in Salt Lake City, Utah.Read More Beat the Market (BTM) Rank™ 1.3 Analyst's Opinion Consensus RatingCo-Diagnostics has received a consensus rating of Buy. The company's average rating score is 2.50, and is based on 1 buy rating, 1 hold rating, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $3.00, Co-Diagnostics has a potential downside of 65.9% from its current price of $8.80.Amount of Analyst CoverageCo-Diagnostics has only been the subject of 2 research reports in the past 90 days. Previous Next 2.3 Community Rank Outperform VotesCo-Diagnostics has received 233 “outperform” votes. (Add your “outperform” vote.)Underperform VotesCo-Diagnostics has received 264 “underperform” votes. (Add your “underperform” vote.)Community SentimentCo-Diagnostics has received 53.12% “underperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Co-Diagnostics and other stocks. Vote “Outperform” if you believe CODX will outperform the S&P 500 over the long term. Vote “Underperform” if you believe CODX will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldCo-Diagnostics does not currently pay a dividend.Dividend GrowthCo-Diagnostics does not have a long track record of dividend growth. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Co-Diagnostics insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 9.00% of the stock of Co-Diagnostics is held by insiders.Percentage Held by InstitutionsOnly 3.70% of the stock of Co-Diagnostics is held by institutions. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Co-Diagnostics are expected to decrease by -100.00% in the coming year, from $0.77 to $0.00 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Co-Diagnostics is -23.78, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Co-Diagnostics is -23.78, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioCo-Diagnostics has a P/B Ratio of 88.00. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next Analyst Opinion: 1.3Community Rank: 2.3Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -Overall Beat the Market Rank™0.71 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Surgical & medical instruments Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:CODX Previous Symbol CUSIPN/A CIK1692415 Webhttp://www.codiagnostics.com/ Phone801-438-1036Debt Debt-to-Equity RatioN/A Current Ratio4.83 Quick Ratio4.23Price-To-Earnings Trailing P/E RatioN/A Forward P/E Ratio11.43 P/E GrowthN/A Sales & Book Value Annual Sales$220,000.00 Price / Sales1,097.60 Cash FlowN/A Price / Cash FlowN/A Book Value$0.10 per share Price / Book88.00Profitability EPS (Most Recent Fiscal Year)($0.36) Net Income$-6,200,000.00 Net Margins-2,881.40% Return on Equity-160.48% Return on Assets-141.88%Miscellaneous Employees22 Outstanding Shares27,440,000Market Cap$241.47 million Next Earnings Date5/20/2020 (Estimated) OptionableNot Optionable Receive CODX News and Ratings via Email Sign-up to receive the latest news and ratings for CODX and its competitors with MarketBeat's FREE daily newsletter. NASDAQ:CODX Rates by TradingView Co-Diagnostics (NASDAQ:CODX) Frequently Asked Questions How has Co-Diagnostics' stock been impacted by COVID-19 (Coronavirus)? Co-Diagnostics' stock was trading at $13.19 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, CODX stock has decreased by 33.3% and is now trading at $8.80. View which stocks have been most impacted by Coronavirus. Do Wall Street analysts recommend investors buy shares of Co-Diagnostics? 2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Co-Diagnostics in the last year. There are currently 1 hold rating and 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Co-Diagnostics. When is Co-Diagnostics' next earnings date? Co-Diagnostics is scheduled to release its next quarterly earnings announcement on Wednesday, May 20th 2020. View our earnings forecast for Co-Diagnostics. How were Co-Diagnostics' earnings last quarter? Co-Diagnostics Inc (NASDAQ:CODX) announced its quarterly earnings data on Tuesday, March, 31st. The company reported ($0.09) earnings per share for the quarter, meeting the Thomson Reuters' consensus estimate of ($0.09). The business had revenue of $0.11 million for the quarter, compared to analysts' expectations of $0.15 million. Co-Diagnostics had a negative net margin of 2,881.40% and a negative return on equity of 160.48%. View Co-Diagnostics' earnings history. What guidance has Co-Diagnostics issued on next quarter's earnings? Co-Diagnostics issued an update on its fourth quarter earnings guidance on Tuesday, March, 31st. The company provided EPS guidance of ($0.36) for the period, compared to the Thomson Reuters consensus earnings per share estimate of ($0.09). The company issued revenue guidance of $214.97 million, compared to the consensus revenue estimate of $0.10 million. What price target have analysts set for CODX? 2 analysts have issued 1-year target prices for Co-Diagnostics' shares. Their forecasts range from $2.00 to $4.00. On average, they anticipate Co-Diagnostics' share price to reach $3.00 in the next twelve months. This suggests that the stock has a possible downside of 65.9%. View analysts' price targets for Co-Diagnostics. Has Co-Diagnostics been receiving favorable news coverage? Media stories about CODX stock have been trending very negative this week, InfoTrie Sentiment reports. The research firm scores the sentiment of press coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Co-Diagnostics earned a news impact score of -3.3 on InfoTrie's scale. They also gave news coverage about the company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an impact on the company's share price in the immediate future. View the latest news aboutCo-Diagnostics. Who are some of Co-Diagnostics' key competitors? Some companies that are related to Co-Diagnostics include Axonics Modulation Technologies (AXNX), Tactile Systems Technology (TCMD), Cerus (CERS), Cryolife (CRY), Orthopediatrics (KIDS), OraSure Technologies (OSUR), Orthofix Medical (OFIX), LeMaitre Vascular (LMAT), SurModics (SRDX), Anika Therapeutics (ANIK), Antares Pharma (ATRS), MiMedx Group (MDXG), AngioDynamics (ANGO), GenMark Diagnostics (GNMK) and SI-Bone (SIBN). What other stocks do shareholders of Co-Diagnostics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Co-Diagnostics investors own include Inovio Pharmaceuticals (INO), Novavax (NVAX), Opko Health (OPK), Tonix Pharmaceuticals (TNXP), Ibio (IBIO), Onconova Therapeutics (ONTX), Advanced Micro Devices (AMD), Moderna (MRNA), Nokia Oyj (NOK) and Gilead Sciences (GILD). Who are Co-Diagnostics' key executives? Co-Diagnostics' management team includes the following people: Mr. Dwight H. Egan, Chairman, CEO & Pres (Age 66)Dr. Brent C. Satterfield, Co-Founder, Chief Science Officer & Director (Age 42)Mr. Reed L. Benson, CFO, Gen. Counsel & Sec. (Age 71)Dr. Mayuranki Almaula, Sr. VP of Overseas Operations & Strategic AlliancesMr. Cameron Gundry, Head of Commercialization LATAM/EUR When did Co-Diagnostics IPO? (CODX) raised $9 million in an initial public offering (IPO) on Thursday, July 13th 2017. The company issued 1,300,000 shares at a price of $6.35-$6.75 per share. WallachBeth Capital and Network 1 Securities served as the underwriters for the IPO. What is Co-Diagnostics' stock symbol? Co-Diagnostics trades on the NASDAQ under the ticker symbol "CODX." How do I buy shares of Co-Diagnostics? Shares of CODX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Co-Diagnostics' stock price today? One share of CODX stock can currently be purchased for approximately $8.80. How big of a company is Co-Diagnostics? Co-Diagnostics has a market capitalization of $241.47 million and generates $220,000.00 in revenue each year. The company earns $-6,200,000.00 in net income (profit) each year or ($0.36) on an earnings per share basis. Co-Diagnostics employs 22 workers across the globe. View additional information about Co-Diagnostics. What is Co-Diagnostics' official website? The official website for Co-Diagnostics is http://www.codiagnostics.com/. How can I contact Co-Diagnostics? Co-Diagnostics' mailing address is 2401 SOUTH FOOTHILL DRIVE SUITE D, SALT LAKE CITY UT, 84109. The company can be reached via phone at 801-438-1036 or via email at [email protected] This page was last updated on 4/10/2020 by MarketBeat.com StaffFeatured Article: Gap Down Stocks
